Antineutrophil cytoplasmic antibodies

Arthritis and Rheumatism

Volumn 41, Issue 9, 1998, Pages 1521-1537

  Hoffman, Gary S ^a   Specks, Ulrich ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AZUROCIDIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN G; ELASTASE; HYDRALAZINE; LACTOFERRIN; MINOCYCLINE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; CHURG STRAUSS SYNDROME; DRUG INDUCED DISEASE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTORY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; INFECTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0031658145     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A     Document Type: Review

References (223)

1. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbo-virus aetiology. BMJ 1982;285:606.
2. Hall JB, Wadham BM, Wood CJ, Ashton V, Adam WR. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med 1984;14:277-8.
3. Van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Perman H, van Es LA. et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
4. Savage COS, Winearls CG, Jones S, Marshall PD, Lockwood CM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 1987;1:1389-93.
5. Cohen Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-5.
6. Specks U, Wheatley CL, McDonald TJ, Rohrbach MS, DeRemee RA. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clin Proc 1989;64: 28-36.
7. Nölle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value. Ann Intern Med 1989;111:28-40.
8. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;25:1651-7.
9. Jenne DE, Tschopp J, Lüdemann J, Utecht B, Gross WL. Wegener's autoantigen decoded. Nature 1990;346:520.
10. Lüdemann J, Csernok E, Ulmer M, Lemke H, Utecht B, Rautmann A, et al. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis: immunodiagnostic value, monoclonal antibodies and characterization of the target antigen. Neth J Med 1990;36:157-62.
11. Jennette JC, Hoidal JR, Falk RJ. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 1990;75: 2263-4.
12. Niles JL, Ahmad MR, McCluskey RT, Arnaout MA. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3 [letter]. Blood 1990;75:2264.
13. Koderisch J, Andrassy K, Rasmussen N, Hartmann M, Tilgen W. "False-positive" anti-neutrophil cytoplasmic antibodies in HIV infection. Lancet 1990;335:1227-8.
14. Lesavre P. Antineutrophil cytoplasmic autoantibodies antigen specificity. Am J Kidney Dis 1991;18:159-63.
15. Klaassen RJL, Goldschmeding R, Dolman KM, Vlekke ABJ, Weigel HM, Eeftinck Schattenkerk JKM, et al. Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection. Clin Exp Immunol 1992;87:24-30.
16. Hauschild S, Schmitt WH, Csernok E, Flesch BK, Rautmann A, Gross WI. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 1993;336:245-51.
17. Segelmark M, Baslund B, Weislander J. Some patients with anti-myeloperoxidase autoantibodies have a C-ASfCA pattern. Clin Exp Immunol 1994;96:458-65.
18. Yang JJ, Tuttle R, Falk RJ, Jennette JC. Frequency of antibactericidal/permeability-increasing protein (BPI) and antiazurocidin in patients with renal disease. Clin Exp Immunol 1996;105:125-31.
19. Zhao MH, Jones SJ, Lockwood CM. Bacteriocidal/permeability-increasing protein (BPI) is an important antigen for antineutrophil cytoplasm autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1996;99:49-56.
20. Wiik A, van der Woude FJ. The new ACPA/ANCA nomenclature. Neth J Med 1990;35:107-8.
21. Cohen Tervaert JW, Goldschmeding R, Elema JD, Limburg PC, van der Giessen M, Huitema MG, et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990;33:1264-72.
22. Nässberger L, Jonsson H, Sjöholm AG, Sturfelt G. Circulating anti-elastase in systemic lupus erythematosus [letter]. Lancet 1989;1:509.
23. Cohen Tervaert JW, Mulder L, Stegeman C, Elema J, Huitema M, The H, et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis 1993;52:115-20.
24. Halbwachs-Mecarelli L, Nusbaum P, Noel LH, Remaux D, Erlinger S. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992;90: 79-84.
25. Sobajima J, Ozaki S, Osakada F, Uesugi H, Shirakawa H, Yoshida M, et al. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins. HMG1 and HMG2. Clin Exp Immunol 1997;107:135-40.
26. Yahya TM, Benedict S, Shalabi A, Bayoumi R. Anti-neutrophil cytoplasmic antibody (ANCA) in malaria is directed against cathepsin G. Clin Exp Immunol 1997;110:41-4.
27. Coremans IEM, Hagen EC, Daha MR, van der Woude FJ, van der Voort EAM, Kleijburg-van der Keur C, et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992;35:1466-75.
28. Mulder AHL, Broekroelofs J, Horst G, Limburg PC, Nelis GF, Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 1994;95:490-7.
29. Broekroelofs J, Mulder AHL, Nelis GF, Westerveld BD, Cohen Tervaert JW, Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD): relation to disease pattern and disease activity. Dig Dis Sci 1994;39:545-9.
30. Bang la Cour B, Wiik A, Møier-Madsen M, Baslund B. Clinical correlates and substrate specificities of antibodies exhibiting neutrophil nuclear reactivity - a methodological study. J Immunol Methods 1995;187:287-95.
31. Zhao MH, Lockwood CM. Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996;103:397-402.
32. Stoffel MP, Csernok E, Herzberg C, Johnston T, Carroll SF, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996;104:54-9.
33. Schultz H, Csernok E, Johnston TW, Lockwood CM, Gross WL. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. J Immunol Methods 1997;205:127-33.
34. Jennings JG, Chang L, Savige JA. Anti-proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol 1994;95:251-6.
35. Specks U, Wiegert EM, Homburger HA. Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 1997;109:286-95.
36. Hertervig E, Wieslander J, Johansson C, Wiik A, Nilsson A. Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease: prevalence and diagnostic role. Scand J Gastroenterol 1995;30:693-8.
37. Mulder AH, Horst G, van Leeuwen MA, Limburg PC, Kallenberg CGM. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlations. Arthritis Rheum 1993;36:1054-60.
38. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis Rheum 1995;38:633-7.
39. Kossa K, Coulthart A, Ives CT, Pusey CD, Hodgson HJF. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7:783-9.
40. Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol 1996;23: 826-30.
41. Specks U, Homburger HA. Anti-neutrophil cytoplasmic antibodies. Mayo Clin Proc 1994;69:1197-8.
42. Bini P, Gabay JE, Teitel A, Melchior M, Zhou J-L, Elkon KB. Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitopes on proteinase 3. J Immunol 1992;149:1409-15.
43. Lüdemann J, Utecht B, Gross WL. Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Methods 1988;114:167-74.
44. Rasmussen N, Sjölin C, Isaksson B, Bygren P, Wieslander J. An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA). J Immunol Methods 1990;127:139-45.
45. Leid RW, Ballieux BEPB, van der Heijden I, Kleyburg-van der Keur C, Hagen EC, van der Woude FJ, et al. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3. Eur J Immunol 1993;23:2939-44.
46. Gaskin G, Kendal H, Coulthart A, Turner N, Pusey CD. Use of proteinase 3 purified by reverse phase HPLC to detect autoantibodies in systemic vasculitis. J Immunol Methods 1995;180:25-33.
47. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross WL, et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): a report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996;196:1-15.
48. Zhao M-H, Lockwood CM. A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 1996;197:121-30.
49. Wieslander J. How are antineutrophil cytoplasmic antibodies detected? Am J Kidney Dis 1991;18:154-8.
50. Specks U, Homburger HA, DeRemee RA. Implications of c-ANCA testing for the classification of Wegener's granulomatosis: performance of different detection systems. Adv Exp Med Biol 1993;336:65-70.
51. Wang G, Csernok E, de Groot K, Gross WL. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 1997;208:203-11.
52. Audrain MA, Baranger TA, Lockwood CM, Esnault VL. High immunoreactivity of lactoferrin contaminating commercially purified myeloperoxidase. J Immunol Methods 1994;176:23-31.
53. Esnault VLM, Short AK, Audrain MAP, Jones SJ, Martin SJ, Skehel JM, et al. Autoantibodies to lactoferrin and histone in systemic vasculitis identified by anti-myeloperoxidase solid phase assays. Kidney Int 1994;46:153-60.
54. Velosa JA, Homburger HA, Holley KE. Prospective study of anti-neutrophil cytoplasmic autoantibody tests in the diagnosis of idiopathic necrotizing-crescentic glomerulonephritis and renal vasculitis. Mayo Clin Proc 1993;68:561-5.
55. Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem TH, et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990;37:799-806.
56. Baslund B, Segelmark M, Wiik A, Szpirt W, Petersen J, Wieslander J. Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? Clin Exp Immunol 1995;99:486-92.
57. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997;126:866-73.
58. Sun J, Pass DN, Hudson JA, Viss MA, Homburger HA, Specks U. Capture-ELISA based on recombinant proteinase 3 (PR3) is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immune complexes. J Immunol Methods 1998; 221:111-23.
59. Sommarin Y, Rasmussen N, Wieslander J. Characterization of monoclonal antibodies to proteinase 3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995;3:249-56.
60. Edgar JDM, McMillan SA, Bruce IN, Conlan SK. An audit of ANCA in routine clinical practice. Postgrad Med J 1995;71:605-12.
61. Savige JA, Smith CL, Chang L, Duggan JC. Anti-neutrophil cytoplasmic antibodies (ANCA) in myelodysplasia and other haematologic disorders. Aust N Z J Med 1994;24:282-7.
62. Hull DR, McMillan SA, Rea IM, Boyd N, McMullin MF. Antineutrophil cytoplasmic antibodies in myelodysplasia. Ulster Med J 1996;65:55-7.
63. Pietravalle P, Monteleone G, Morano S, Cristina G, de Rossi MG, Sagratella E, et al. Antineutrophil cytoplasmic antibodies are present in long standing type 1 diabetics but do not correlate with selective proteinuria. J Autoimmun 1996;9:113-7.
64. Yenning MC, Quinn A, Broomhead V, Bird AG. Antibodies directed against neutrophils (c-ANCA and p-ANCA) are of distinct diagnostic value in systemic vasculitis. QJM 1990;77: 1287-96.
65. Savige JA, Gallicchio M, Georgiou T, Davies DJ. Diverse target antigens recognized by circulating antibodies in antineutrophil cytoplasm antibody-associated renal vasculitides. Clin Exp Immunol 1990;82:238-43.
66. Gaskin G, Savage COS, Jones RS, Rees AJ, Lockwood CM, Pusey CD. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-94.
67. Bosch X, Mirapeix E, Font J, Cervera R, Ingelmo M, Khamashta MA, et al. Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis. Am J Kidney Dis 1992;20:231-9.
68. Sinico RA, Radice A, Pozzi C, Ferrario F, Arrigo G. Diagnostic significance and antigen specifity of antineutrophil cytoplasmic antibodies in renal diseases: a prospective multicentre study. Nephrol Dial Transplant 1994;9:505-10.
69. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995;88:127-33.
70. Falk RJ, Hogan S, Carey TS, Jennette JC, Network GDC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;11:656-63.
71. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-71.
72. Davenport A, Lock RJ, Wallington TB, Feest TG. Clinical significance of anti-neutrophil cytoplasm antibodies detected by a standardized indirect immunofluorescence assay. QJM 1994;87: 291-9.
73. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
74. Cohen Tervaert JW, Kallenberg CGM. Anti-myeloperoxidase antibodies in Churg-Strauss syndrome. J Neurol 1993;240:449-52.
75. Guillevin L, Visser H, Noel LH, Pourrat J, Vernier I, Gayraud M, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome - 62 patients. J Rheumatol 1993;20: 1345-9.
76. Hauschild S, Csernok E, Schmitt WH, Gross WL. Antineutrophil cytoplasmic antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss Syndrome - 62 patients. J Rheumatol 1994;21:1173-4.
77. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol 1995;7:20-4.
78. Jennette JC, Falk RJ, Andrassy K, Bacon BA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92.
79. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/ permeability-increasing protein in patients with cystic fibrosis. QJM 1996;89:259-65.
80. Burrows NP, Norris PG, Zhao MH, Lockwood CM. ANCA associated with Behçet's disease. J R Soc Med 1996;89:47P-8P.
81. Esnault VL, Ronda N, Jayne DR, Lockwood CM. Association of ANCA isotype and affinity with disease expression. J Autoimmun 1993;6:197-205.
82. Ronda N, Esnault VLM, Layward L, Allen VSA, Feehally J, Lockwood CM. Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schönlein purpura. Clin Exp Immunol 1994;95:49-55.
83. Saulsbury FT, Kirkpatrick PR, Bolton WK. IgA antineutrophil cytoplasmic antibody in Henoch-Schonlein purpura. Am J Nephrol 1991;11:295-300.
84. Robson WL, Leung AK, Woodman RC. The absence of anti-neutrophil cytoplasmic antibodies in patients with Henoch-Schonlein purpura. Pediatr Nephrol 1994;8:295-8.
85. Kaneko K, Suzuki Y, Yabuta K. Absence of anti-neutrophil cytoplasmic antibody (ANCA) in Henoch-Schonlein purpura and immunoglobulin A nephropathy. Acta Paediatr Jpn 1994;36:619-22.
86. Guzman J, Fung M, Petty RE. Diagnostic value of anti-neutrophil cytoplasmic and anti-endothelial cell antibodies in early Kawasaki disease. J Pediatr 1994;124:917-20.
87. Nash MC, Shah V, Reader JA, Dillon MJ. Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol 1995;34: 882-7.
88. Baranger TA, Audrain MA, Castagne A, Barrier JH, Esnault VL. Absence of antineutrophil cytoplasmic antibodies in giant cell arteritis. J Rheumatol 1994;21:871-3.
89. Eichhorn J, Sima D, Thiele B, Lindschau C, Turowski A, Schmidt H, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation 1996;94:2396-401.
90. Savige JA, Gallicchio MC, Stockman A, Cunningham TJ, Rowley MJ, Georgiou T, et al. Anti-neutrophil cytoplasm antibodies in rheumatoid arthritis. Clin Exp Immunol 1991;86:92-8.
91. Bosch X, Llena J, Collado A, Font J, Mirapeix E, Ingelmo M, et al. Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. J Rheumatol 1995;22:2038-45.
92. Afeltra A, Sebastiani GD, Galeazzi M, Caccavo D, Ferri GM, Marcolongo R, et al. Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. J Rheumatol 1996;23:10-5.
93. Akimoto S, Ishikawa O, Tamura T, Miyachi Y. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br J Dermatol 1996;134:407-10.
94. Röther E, Schochat T, Peter HH. Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study. Rheumatol Int 1996;15:231-7.
95. De Bandt M, Meyer O, Haim T, Kahn MF. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br J Rheumatol 1996;35:38-43.
96. Mustila A, Korpela M, Mustonen J, Helin H, Huhtala H, Soppi E, et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum 1997;40:710-7.
97. Mulder L, van Rossum M, Horst G, Limburg P, de Graeff-Meeder ER, Kuis W, et al. Antineutrophil cytoplasmic antibodies in juvenile chronic arthritis. J Rheumatol 1997;24:568-75.
98. Helsloot J, Virgo S, McGuigan L, Sturgess A. Antineutrophil cytoplasmic antibodies in inflammatory arthritis - potential for misdiagnosis. Br J Rheumatol 1995;34:820-4.
99. Locht H, Peen E, Skogh T. Antineutrophil cytoplasmic antibodies in reactive arthritis. J Rheumatol 1995;22:2304-6.
100. Papo T, Piette JC, Du LTH, Godeau P, Meyer O, Kahn MF, et al. Antineutrophil cytoplasmic antibodies in polychondritis. Ann Rheum Dis 1993;52:384-5.
101. Handrock K, Gross WL. Relapsing polychondritis as a secondary phenomenon of primary systemic vasculitis. Ann Rheum Dis 1993;52:895-6.
102. Kawachi Y, Nukaga H, Hoshino M, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin Exp Dermatol 1995;20:345-7.
103. Locke IC, Worrall JG, Leaker B, Black CM, Cambridge G. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997;24:86-9.
104. Coremans IE, Hagen EC, van der Voort EA, van der Woude FJ, Daha MR, Breedveld FC. Autoantibodies to neutrophil cytoplasmic enzymes in Felty's syndrome. Clin Exp Rheumatol 1993;11:255-62.
105. Spronk PE, Boostma H, Horst G, Huitema MG, Limburg PC, Cohen Tervaert JW, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996;35:625-31.
106. Saxon A, Shanahan F, Landers C, Ganz R, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86: 202-10.
107. Rump JA, Schölmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990;181:406-13.
108. Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun 1997;10:175-80.
109. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996;105:120-4.
110. Walmsley RS, Zhao MH, Hamilton MI, Brownlee A, Chapman P, Pounder RE, et al. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 1997;40:105-9.
111. Billing P, Tahir S, Calfin B, Gagne G, Cobb L, Targan S, et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995;147:979-87.
112. Castellino F, Rosina F, Bansi DS, Bauduci M, Touscoz GA, Giorda L, et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease - do they recognize different subsets of a heterogeneous disease? Eur J Gastroenterol Hepatol 1995;7: 859-64.
113. Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can J Gastroenterol 1997;11:203-7.
114. Vasiliauskas EA, Plevy SC, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-9.
115. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-6.
116. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenteol 1995;90: 740-7.
117. Aitola P, Miettinen A, Mattila A, Matikainen M, Soppi E. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol 1995;48:645-7.
118. Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385-91.
119. Haagsma EB, Mulder AHL, Gouw ASH, Horst G, Meerman L, Slooff MJH, et al. Neutrophil cytoplasmic autoantibodies after liver transplantation in patients with primary sclerosing cholangitis. J Hepatol 1993;19:8-14.
120. Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St. Louis P, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-22.
121. Targan SR, Landers C, Vidrich A, Czaja AJ. High-liter antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108:1159-66.
122. Gur H, Shen G, Sutjita M, Terrberry J, Alosachie I, Barka N, et al. Autoantibody profile in primary sclerosing cholangitis. Pathobiology 1995;63:76-82.
123. Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997;25:1105-7.
124. Orth T, Gerken G, Kellner R, Meyer zum Buschenfelde KH, Mayet WJ. Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. J Hepatol 1997;26:37-47.
125. Nässberger L, Sjoholm AG, Jonsson H, Sturfelt G, Akesson A. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990;81:380-3.
126. Jones BF, Major GAC. Crescentic glomerulonephritis in a patient taking penicillamine associated with antineutrophil cytoplasmic antibody [letter]. Clin Nephrol 1992;38:293.
127. Dolman KM, Gans ROB, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
128. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomeulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8.
129. Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 1995;88:775-83.
130. Tanemoto M, Miyakawa H, Hanai J, Yago M, Kitaoka M, Uchida S. Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Am J Kidney Dis 1995;26: 774-80.
131. Eklayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996;55:769-71.
132. D'Cruz D, Chesser AMS, Lightowler C, Comer M, Hurst MJ, Baker LRI, et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 1995;34:1090-1.
133. Yuasa S, Hashimoto M, Yura T, Sumikura T, Takahashi N, Shoji T, et al. Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Nephron 1996;73:701-3.
134. Kitahara T, Hiromura K, Maezawa A, Ono K, Narabara N. Yano S, et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA): review of literature. Clin Nephrol 1997;47:336-40.
135. Wagner J, Andrassy K, Ritz E. Is vasculitis in subacute bacterial endocarditis associated with ANCA? Lancet 1991;337:799-800.
136. Soto A, Jorgensen C, Oksman F, Noel LH, Sany J. Endocarditis associated with ANCA. Clin Exp Rheumatol 1994;12:203-4.
137. Efthimiou J, Spickett G, Lane D, Thompson A. Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet 1991;337:1037.
138. Davenport A, Lock RJ, Wallington TB. Clinical relevance of testing for antineutrophil cytoplasm antibodies (ANCA) with a standard indirect immunofluorescence ANCA test in patients with upper or lower respiratory tract symptoms. Thorax 1994;49: 213-7.
139. Galperin C, Shoenfeld Y, Gilburd B, Esterre P, Meroni PL, Del Papa N, et al. Anti-neutrophil cytoplasmic antibodies in patients with chromomycosis. Clin Exp Rheumatol 1996;14:479-83.
140. Lesavre P, Noel LH, Gayno S, Nusbaum P, Reumaux D, Erlinger S, et al. Atypical autoantigen targets of perinuclear antineutrophil cytoplasm antibodies (P-ANCA): specificity and clinical associations. J Autoimmun 1993;6:185-95.
141. Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity 1994;18: 205-11.
142. Wenisch C, Wenisch H, Bankl H-C, Exner M, Graninger W, Looareesuwan S, et al. Detection of anti-neutrophil cytoplasmic antibodies after acute Plasmodium falciparum malaria. Clin Diagn Lab Immunol 1996;3:132-4.
143. Pudifin DJ, Duursma J, Gathiram V, Jackson TFHG. Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody. Clin Exp Immunol 1994;97:48-51.
144. De Clerck LS, van Offel JF, Smolders WA, Empsten FA, Bridts CH, Bourgeois N, et al. Pitfalls with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Rheumatol 1989;8:512-6.
145. Cho CD, Asuncion A, Tatum AH. False-positive antineutrophil cytoplasmic antibody in aspergillosis with oxalosis. Arch Pathol Lab Med 1995;119:558-61.
146. Davenport A. "False positive" perinuclear and cytoplasmic anti-neutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener's granulomatosis and/or microscopic polyarteritis. Clin Nephrol 1992;37:124-30.
147. Van de Wiel BA, Dolman KM, van der Meer-Gerritsen CH, Nack CE, von dem Borne AEGK, Goldschmeding R. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992;90:409-14.
148. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degraunlate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87:4115-9.
149. Charles LA, Caldas MLR, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991;50:539-46.
150. Keogan MT, Esnault VLM, Green AJ, Lockwood CM, Brown DL. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1992;90:228-34.
151. Brouwer E, Huiteman MG, Mulder AHL, Heeringa P, van Goor H, Cohen Tervaert JW, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994;45:1120-31.
152. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;98:244-50.
153. Mulder AHL, Heeringa P, Brouwer E, Limburg PC, Kallenberg CGM. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a FcγRII-dependent process. Clin Exp Immunol 1994;98:270-8.
154. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγR11a. J Immunol 1994;153: 1271-80.
155. Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 1995;374:29-33.
156. Reumaux D, Vossebeld PJM, Roos D, Verhoeven AJ. Effect of tumor necrosis factor-induced integrin activation on Fcγ receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995;86:3189-95.
157. Nachman PH, Reisner HM, Yang JJ, Jennette JC, Falk RJ. Shared idiotypy among patients with myeloperoxidase-anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. Lab Invest 1996;74:519-27.
158. Audrain MAP, Baranger TAR, Moguilevski N, Martin SJ, Devys A, Lockwood CM, et al. Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. Clin Exp Immunol 1997;107:127-34.
159. Dolman KM, Stegeman CA, van de Wiel BA, Hack CE, von dem Borne AEGK, Kallenberg CGM, et al. Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-a1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 1993; 93:405-10.
160. Devaney KO, Travis WD, Hoffman G, Leavitt R, Lebovics R, Fauci AS. Interpretation of head and neck biopsies in Wegener's granulomatosis. Am J Surg Pathol 1990;14:555-64.
161. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Am J Surg Pathol 1991;15:315-33.
162. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
163. Bajema IM, Hagen EC, Ferrario F, Waldherr R, Noel LH, Hermans J, et al. Renal granulomas in systemic vasculitis: EC/BCR project for ANCA-assay standardization. Clin Nephrol 1997;48:16-21.
164. Mark EJ, Matsubara O, Tan-Liu Ns, Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum Pathol 1988;19:1065-71.
165. Wegener F. Wegener's granulomatosis: thoughts and observations of a pathologist. Eur Arch Otorhinolaryngol 1990;247:133-42.
166. Colby TV, Specks U. Wegener's granulomatosis in the 1990s - a pulmonary pathologist's perspective. Monogr Pathol 1993;36: 195-218.
167. Hagen EC, Ballieux EPB, van Es LA, Daha MR, van der Woude FJ. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood 1993;81:1996-2002.
168. Rao JY, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. Ann Intern Med 1995;123:425-32.
169. Henshaw TJ, Malone CC, Gabay JE, Williams RC Jr. Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis Rheum 1994; 37:104-12.
170. Hoffman GW, Sechler JMG, Gallin JI, Shelhamer JH, Suffredini A, Ognibene P, et al. Bronchoalveolar lavage analysis in Wegener's granulomatosis. Am Rev Respir Dis 1991;143:410-7.
171. Barth J, Petermann W, Zemke F, Kreipe H, Gross WL. Bronchoalveoläre lavage bei Wegenerscher granulomatose. Pneumologie 1991;45:570-4.
172. Mrowka C, Csernok E, Gross WL, Feucht HE, Bechtel U, Thoenes GH. Distribution of the granulocyte serine proteinases proteinase 3 and elastase in human glomerulonephritis. Am J Kidney Dis 1995;25:253-61.
173. Ballieux BEPB, Hiemstra PS, Klar-Mohamad N, Hagen EC, van Es LA, van der Woude FJ, et al. Detachment and cytolysis of human endothelial cells by proteinase 3. Eur J Immunol 1994;24: 3211-5.
174. Yang JJ, Kettritiz R, Falk RJ, Jennette JC, Gaido ML. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol 1996;149:1617-26.
175. Savage CO, Gaskin G, Pusey CD, Pearson JD. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol 1993;1:190-5.
176. Ballieux BEPB, Zondervan KT, Kievit P, Hagen EC, van Es LA, van der Woude FJ, et al. Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC? Clin Exp Immunol 1994;97:52-60.
177. Peen E, Sundqvist T, Skogh T. Leucocyte activation by antilactoferrin antibodies bound to vascular endothelium. Clin Exp Immunol 1996;103:703-7.
178. Oseas R, Yang HH, Baehner RL, Boxer LA. Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. Blood 1981;57:939-45.
179. Savage COS, Cooke SP. The role of the endothelium in systemic vasculitis. J Autoimmun 1993;6:237-49.
180. Gilligan HM, Bredy B, Brady HR, Hebert MJ, Slayter HS, Xu Y, et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996;184: 2231-41.
181. Williams RC, Jr, Staud R, Malone CC, Payabyab J, Byres L, Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 1994;152:4722-37.
182. Mulder AHL, Stegeman CA, Kallenberg CGM. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995;101:227-32.
183. Wainstein E, Edberg J, Csernok E, Sneller M, Hoffman G, Keystone E, et al. FcγRIIIB alleles predict renal dysfunction in Wegeners granulomatosis [abstract]. Arthritis Rheum 1996;39 Suppl 9:210.
184. Mayet W-J, Csernok E, Szymkowiak C, Gross AWL, Meyer zum Büschenfelde K-H. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993;82:1221-9.
185. King WJ, Adu D, Daha MR, Brooks CJ, Radford DJ, Pall AA, et al. Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 1995; 102:98-105.
186. Berger SP, Seelen MAJ, Hiemstra PS, Gerritsma JSJ, Heemskerk E, van der Woude FJ, et al. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol 1996;7:694-701.
187. Mayet WJ, Meyer zum Büschenfelde K-H. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:440-60.
188. Mayet WJ, Schwarting A, Orth T, Duchmann R, Meyer zum Büschenfelde K-H. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996;103:259-67.
189. Rastaldi MP, Ferrario F, Tunesi S, Yang L, D'Amico G. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1a expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 1996;27:48-57.
190. Van der Woude FJ, van Es LA, Dahan MR. The role of the c-ANCA antigen in the pathogenesis of Wegener's granulomatosis: a hypothesis based on both humoral and cellular mechanisms. Neth J Med 1990;36:169-71.
191. Brouwer E, Stegeman CA, Huitema MG, Limbug PC, Kallenberg CGM. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1994;98:448-53.
192. Ballieux BEPB, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJM, Daha MR. Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1995; 100:186-93.
193. Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996;103:253-8.
194. Casselman BL, Kilgore KS, Miller BF, Warren JS. Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. J Lab Clin Med 1995;126:495-502.
195. Brooks CJ, King WJ, Radford DJ, Adu D, McGrath M, Savage COS. IL-1β production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996;106:273-9.
196. Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release: role of surface proteinase-3, α1-antitrypsin, and fcγ receptors. J Clin Invest 1997;100:1416-24.
197. Grimminger F, Hattar K, Papavassilis C, Temmesfeld B, Csernok E, Gross WL, et al. Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med 1996; 184:1567-72.
198. Esnault VLM, Testa A, Audrain M, Rogé C, Hamidou M, Barrier JH, et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993;43:1329-32.
199. Elzouki A-NY, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994;236:543-8.
200. Segelmark M, Elzouki A-N, Wieslander J, Eriksson S. The PiZ gene of α1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 1995;48:844-50.
201. Lhotta K, Vogel W, Meisi T, Buxbaum M, Neyer U, Sandholzer C, et al. α1-Antitrypsin phenotypes in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. Clin Sci 1994; 87:693-5.
202. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1 antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996;11:438-43.
203. Baslund B, Szpirt WA, Eriksson S, Elzouki AN, Wiik A, Wieslander J, et al. Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Eur J Clin Invest 1996;26:786-92.
204. Cohen Tervaert JW, Stegeman CA, Kallenberg CGM. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Sarcoidosis Vase Diffuse Lung Dis 1996;13:241-5.
205. Jennette JC, Falk RJ. Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis. Curr Opin Rheumatol 1992;4:9-15.
206. Cohen Tervaert JW. The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides: a review. J Nephrol 1996;9:232-40.
207. Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997;8:314-22.
208. Wiik AS. Anti-neutrophil cytoplasmic antibodies in primary small vessel vasculitides. Scand J Rheumatol 1996;25:65-9.
209. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomeulonephritis and vasculitis. Am J Pathol 1989;135:921-30.
210. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375-83.
211. Jennette JC, Ewert BH, Falk RJ. Do antineutrophil cytoplasmic autoantibodies cause Wegener's granulomatosis and other forms of necrotizing vasculitis? Rheum Dis Clin North Am 1993;19:1-14.
212. Ewert BH, Becker ME, Jennette JC, Falk RJ. Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. Ren Fail 1995;17:125-33.
213. Mandell BF, Hoffman GS. Differentiating the vasculitides. Rheum Dis Clin North Am 1994;20:409-42.
214. Serra A, Cameron JS, Turner DR, Hartley B, Ogg CS, Neild GH, et al. Vasculitis affecting the kidney: presentation, histopathology and long-term outcome. QJM 1984;53:181-207.
215. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
216. Griffith ME, Gaskin G, Pusey CD. Classification, pathogenesis, and treatment of systemic vasculitis. Ren Fail 1996;18:785-802.
217. Langford CA. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Cleve Clin J Med 1998;65:135-40.
218. Savage COS. Microscopic polyarteritis: definition and relation to Wegener's granulomatosis. APMIS 1989;97:8-9.
219. Schnabel A, Hauschild S, Gross WL. Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Int Arch Allergy Immunol 1996;109:201-6.
220. Cohen Tervaert JW, Huitema MG, Hené RJ, Sluiter WJ, The TH, van der Hem GK, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
221. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992;37:219-28.
222. Jeffrey RF, Khan AA, Davison A, Aparicio S, Gooi HC, Will EJ, et al. Renal disease associated with antineutrophil cytoplasmic antibody: 39 patients over a 5-year period. Br J Clin Pract 1994;48:180-4.
223. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-9.